Literature DB >> 2495202

Reduction in HLA-DR, HLA-DQ and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury.

R A Gibbons1, O M Martinez, R C Lim, J K Horn, M R Garovoy.   

Abstract

Monocytes that bear HLA Class II antigens, such as HLA-DR, HLA-DQ, or HLA-DP, are obligatory for many cell-mediated immunological processes. Patients with thermal injury suffer from hypoimmunity and are at risk for developing life-threatening septic episodes. To determine whether an alteration in expression of HLA Class II antigens is involved in the defect, monocytes from the peripheral blood of burn patients and controls were double-stained with anti-Leu-M3 and either anti-HLA-DR, HLA-DQ, or HLA-DP monoclonal antibodies. As analysed by flow cytometry the percentage of Leu-M3+ monocytes from the peripheral blood from patients and controls was the same. The percentage of Leu-M3+ monocytes bearing the HLA Class II antigens and the density of antigen on the monocytes, however, was significantly reduced post-burn compared with controls. In nearly all cases these changes were detected as early as 24 h post-burn before any drug therapy was implemented. In-vivo re-expression of normal levels of HLA Class II coincided with patient recovery. In-vitro exposure of post-burn Leu-M3+ cells to IFN-gamma for 72 h restored HLA Class II expression to control levels. It is possible that the reductions in HLA Class II expression may be involved in the general immunosuppression that follows thermal injury.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495202      PMCID: PMC1541962     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

Review 1.  Antigen-presenting function of the macrophage.

Authors:  E R Unanue
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

2.  Deficient gamma-interferon production in patients with systemic lupus erythematosus.

Authors:  G C Tsokos; D T Boumpas; P L Smith; J Y Djeu; J E Balow; A H Rook
Journal:  Arthritis Rheum       Date:  1986-10

3.  Changes in immunoglobulin levels in severely burned patients.

Authors:  G Arturson; C F Högman; S G Johansson; J Killander
Journal:  Lancet       Date:  1969-03-15       Impact factor: 79.321

4.  Suppressor cell activity after major injury: indirect and direct functional assays.

Authors:  R M Keane; A M Munster; W Birmingham; C Shatney; R A Winchurch
Journal:  J Trauma       Date:  1982-09

5.  Indomethacin-mediated enhancement of lymphocyte response to mitogens; in treated and untreated Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  T Han; M S Winnicki
Journal:  N Y State J Med       Date:  1980-06

6.  Prostaglandins modulate macrophage Ia expression.

Authors:  D S Snyder; D I Beller; E R Unanue
Journal:  Nature       Date:  1982-09-09       Impact factor: 49.962

7.  Changes in T lymphocyte subsets following injury. Assessment by flow cytometry and relationship to sepsis.

Authors:  J B O'Mahony; J J Wood; M L Rodrick; J A Mannick
Journal:  Ann Surg       Date:  1985-11       Impact factor: 12.969

8.  Depressed interferon gamma production and monocyte HLA-DR expression after severe injury.

Authors:  D H Livingston; S H Appel; S R Wellhausen; G Sonnenfeld; H C Polk
Journal:  Arch Surg       Date:  1988-11

9.  Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies.

Authors:  A Dimitriu-Bona; G R Burmester; S J Waters; R J Winchester
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

10.  Reduced interferon-gamma mRNA levels in human neonates. Evidence for an intrinsic T cell deficiency independent of other genes involved in T cell activation.

Authors:  D B Lewis; A Larsen; C B Wilson
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more
  8 in total

1.  Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis.

Authors:  Philip A Berry; Charalambos G Antoniades; Ivana Carey; Mark J W McPhail; Munther J Hussain; Edward T Davies; Julia A Wendon; Diego Vergani
Journal:  Intensive Care Med       Date:  2010-12-16       Impact factor: 17.440

2.  Reduction in HLA-DR antigen density on alveolar macrophages of smokers.

Authors:  W Pankow; K Neumann; J Rüschoff; R Schröder; P von Wichert
Journal:  Lung       Date:  1991       Impact factor: 2.584

3.  Rationale, design and performance of a clinical trial to investigate interferon-gamma (Imukin) in the prophylactic treatment of severe burns-related infections.

Authors:  J D Ioannovich; R D Hinzmann; G Deichsel; G G Steinmann
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

4.  HLA class II glycoprotein expression by monocytes from HIV-infected individuals: differences in response to interferon-gamma.

Authors:  B S Zwilling; R Darrow; M Mcpeek; H Laufman; D Pearl
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

5.  Early decrease in surface expression of HLA-DQ predicts the development of infection in trauma patients.

Authors:  J V Taylor; L E Gordon; H C Polk
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

6.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Authors:  Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

7.  The relationship between interferon-gamma and keratinocyte alloantigen expression after burn injury.

Authors:  C S Hultman; L M Napolitano; B A Cairns; L A Brady; C Campbell; S deSerres; A A Meyer
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

8.  Severe H7N9 infection is associated with decreased antigen-presenting capacity of CD14+ cells.

Authors:  Hongyan Diao; Guangying Cui; Yingfeng Wei; Jianing Chen; Jian Zuo; Hongcui Cao; Yu Chen; Hangping Yao; Zhigang Tian; Lanjuan Li
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.